Evidence  	Evidence  	 NN	O
for  	for  	 IN	O
S-adenosyl-L-methionine  	S-adenosyl-L-methionine  	 NNP	B-NP
( 	( 	 -LRB-	O
SAM-e 	SAM-e 	 NNP	B-NP
)  	)  	 -RRB-	O
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
major  	major  	 JJ	O
depressive  	depressive  	 JJ	B-NP
disorder  	disorder  	 NN	I-NP
Despite  	Despite  	 IN	O
the  	the  	 DT	O
increasingly  	increasingly  	 RB	O
large  	large  	 JJ	O
array  	array  	 NN	O
of  	of  	 IN	O
antidepressants  	antidepressants  	 JJ	B-NP
available  	available  	 JJ	I-NP
to  	to  	 TO	O
treat  	treat  	 VB	O
major  	major  	 JJ	O
depressive  	depressive  	 JJ	B-NP
disorder 	disorder 	 NN	I-NP
,  	,  	 ,	O
patients  	patients  	 NNS	O
continue  	continue  	 VBP	O
to  	to  	 TO	O
experience  	experience  	 VB	O
relatively  	relatively  	 RB	O
modest  	modest  	 JJ	O
response  	response  	 NN	O
and  	and  	 CC	O
remission  	remission  	 JJ	B-NP
rates 	rates 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
patients  	patients  	 NNS	O
may  	may  	 MD	O
experience  	experience  	 VB	O
adverse  	adverse  	 JJ	O
side  	side  	 NN	B-NP
effects  	effects  	 NNS	I-NP
from  	from  	 IN	O
pharmacotherapy  	pharmacotherapy  	 NNS	B-NP
that  	that  	 WDT	O
not  	not  	 RB	O
only  	only  	 RB	O
hinder  	hinder  	 VB	O
treatment  	treatment  	 NN	B-NP
compliance  	compliance  	 NN	I-NP
and  	and  	 CC	O
adherence  	adherence  	 NNS	O
but 	but 	 CC	O
,  	,  	 ,	O
in  	in  	 IN	O
some  	some  	 DT	O
cases 	cases 	 NNS	O
,  	,  	 ,	O
may  	may  	 MD	O
also  	also  	 RB	O
contribute  	contribute  	 VB	O
to  	to  	 TO	O
increased  	increased  	 JJ	O
disability 	disability 	 NN	O
,  	,  	 ,	O
patient  	patient  	 JJ	O
suffering 	suffering 	 NN	O
,  	,  	 ,	O
morbidity 	morbidity 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
mortality 	mortality 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
order  	order  	 NN	O
to  	to  	 TO	O
enhance  	enhance  	 VB	O
treatment  	treatment  	 NN	B-NP
efficacy  	efficacy  	 NNS	I-NP
and  	and  	 CC	O
tolerability 	tolerability 	 NN	B-NP
,  	,  	 ,	O
patients  	patients  	 NNS	O
and  	and  	 CC	O
clinicians  	clinicians  	 NNS	B-NP
have  	have  	 VBP	O
become  	become  	 VBN	O
increasingly  	increasingly  	 RB	O
interested  	interested  	 VBN	O
in  	in  	 IN	O
nonpharmaceutical  	nonpharmaceutical  	 JJ	B-NP
supplements  	supplements  	 NN	I-NP
for  	for  	 IN	I-NP
treating  	treating  	 VBG	I-NP
depression 	depression 	 NN	I-NP
.  	.  	 .	O
One  	One  	 CD	O
of  	of  	 IN	O
the  	the  	 DT	O
best-studied  	best-studied  	 JJ	O
of  	of  	 IN	O
these  	these  	 DT	O
supplements  	supplements  	 NN	O
is  	is  	 VBZ	O
S-adenosyl-L-methionine  	S-adenosyl-L-methionine  	 JJ	B-NP
( 	( 	 -LRB-	O
SAM-e 	SAM-e 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
a  	a  	 DT	O
naturally  	naturally  	 RB	O
occurring  	occurring  	 VBG	B-NP
molecule  	molecule  	 NN	I-NP
present  	present  	 NN	O
in  	in  	 IN	O
all  	all  	 DT	O
living  	living  	 NN	O
cells  	cells  	 NNS	O
and  	and  	 CC	O
a  	a  	 DT	O
major  	major  	 JJ	O
methyl  	methyl  	 JJ	B-NP
group  	group  	 NN	I-NP
donor  	donor  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
human  	human  	 JJ	O
body 	body 	 NN	O
.  	.  	 .	O
Controlled  	Controlled  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
have  	have  	 VBP	O
found  	found  	 VBN	O
SAM-e  	SAM-e  	 JJ	B-NP
to  	to  	 TO	O
be  	be  	 VB	O
more  	more  	 JJR	O
efficacious  	efficacious  	 NN	O
than  	than  	 IN	O
placebo  	placebo  	 NN	O
and  	and  	 CC	O
equal  	equal  	 JJ	O
in  	in  	 IN	O
efficacy  	efficacy  	 VBG	O
to  	to  	 TO	O
the  	the  	 DT	O
tricyclic  	tricyclic  	 JJ	B-NP
antidepressants  	antidepressants  	 NN	I-NP
for  	for  	 IN	O
treating  	treating  	 VBG	O
major  	major  	 JJ	B-NP
depressive  	depressive  	 JJ	I-NP
disorder  	disorder  	 NN	I-NP
( 	( 	 -LRB-	O
MDD 	MDD 	 NNP	B-NP
)  	)  	 -RRB-	O
when  	when  	 WRB	O
administered  	administered  	 JJ	O
parenterally  	parenterally  	 NNS	O
( 	( 	 -LRB-	O
either  	either  	 DT	O
intravenously  	intravenously  	 NN	O
or  	or  	 CC	O
intramuscularly 	intramuscularly 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Less  	Less  	 JJR	O
evidence  	evidence  	 NN	O
supports  	supports  	 VBZ	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
oral  	oral  	 JJ	B-NP
SAM-e 	SAM-e 	 NN	I-NP
,  	,  	 ,	O
although  	although  	 IN	O
some  	some  	 DT	O
trials  	trials  	 NNS	O
have  	have  	 VBP	O
demonstrated  	demonstrated  	 VBN	O
its  	its  	 PRP$	O
efficacy  	efficacy  	 NN	O
as  	as  	 IN	O
well 	well 	 RB	O
.  	.  	 .	O
In  	In  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
there  	there  	 EX	O
is  	is  	 VBZ	O
a  	a  	 DT	O
paucity  	paucity  	 NN	O
of  	of  	 IN	O
evidence  	evidence  	 NN	O
examining  	examining  	 VBG	O
whether  	whether  	 IN	O
oral  	oral  	 JJ	B-NP
forms  	forms  	 NNS	I-NP
of  	of  	 IN	I-NP
SAM-e  	SAM-e  	 NNP	I-NP
can  	can  	 MD	O
be  	be  	 VB	O
safe 	safe 	 JJ	O
,  	,  	 ,	O
well  	well  	 RB	O
tolerated 	tolerated 	 JJ	O
,  	,  	 ,	O
and  	and  	 CC	O
efficacious  	efficacious  	 NN	O
when  	when  	 WRB	O
used  	used  	 VBN	O
as  	as  	 IN	O
adjunctive  	adjunctive  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
for  	for  	 IN	I-NP
antidepressant  	antidepressant  	 JJ	I-NP
nonresponders  	nonresponders  	 NN	I-NP
with  	with  	 IN	O
MDD 	MDD 	 NNP	B-NP
.  	.  	 .	O
Although  	Although  	 IN	O
preliminary  	preliminary  	 JJ	B-NP
data  	data  	 NNS	I-NP
suggest  	suggest  	 VBP	O
SAM-e  	SAM-e  	 NNS	B-NP
may  	may  	 MD	O
be  	be  	 VB	O
useful  	useful  	 JJ	O
as  	as  	 IN	O
an  	an  	 DT	O
adjunctive  	adjunctive  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
to  	to  	 TO	O
antidepressants 	antidepressants 	 VB	O
,  	,  	 ,	O
controlled  	controlled  	 VBN	B-NP
studies  	studies  	 NNS	I-NP
are  	are  	 VBP	O
needed  	needed  	 VBN	O
to  	to  	 TO	O
confirm  	confirm  	 VB	O
or  	or  	 CC	O
refute  	refute  	 VB	O
these  	these  	 DT	O
preliminary  	preliminary  	 JJ	B-NP
findings 	findings 	 NNS	I-NP
.  	.  	 .	O
